Search

Displaying results 2521 - 2530 of 2955 in total
  1. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from th...

    Mixtures: COUGH - EN, COUGH - EN PLUS
  2. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    On April 29, 2024, tisotumab vedotin was granted full FDA approval. … Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting

  3. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection.

  4. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.

  5. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.

  6. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged.

  7. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients.

  8. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246703] Pralatrexate was approved by the FDA on September 24, 2009.

  9. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563]

  10. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]